bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

1 # Stabilization of α-synuclein oligomers using formaldehyde

2 *Harm Ruesink[a,b,#] and Lasse Reimer[a,b,#], Emil Gregersen[a,b], Arne Moeller[a,c], Cristine Betzer[a,b] and Poul Henning*
3 *Jensen[a,b]*

4 [a]Danish Research Institute of Translational Neuroscience - DANDRITE, Aarhus University, Denmark.

5 [b]Department of Biomedicine, Aarhus University, Denmark.

6 [c]Department of Structural Biology, The Max Planck Institute of Biophysics, Frankfurt, Germany

7 [#]Contributed equally

8

9 ## Abstract

10 The group of neurodegenerative diseases, Parkinson's disease (PD), dementia with Lewy bodies (DLB), and
11 multiple system atrophy (MSA) all exhibit inclusions containing amyloid-type α-synuclein (α-syn) aggregates
12 within degenerating brain cells. α-syn also exists as soluble oligomeric species that are hypothesized to
13 represent intermediates between its native and aggregated states. These oligomers are present in brain
14 extracts from patients suffering from synucleinopathies and hold great potential as biomarkers. Although
15 easily prepared *in vitro,* oligomers are metastable and dissociate over time, thereby complicating α-syn
16 oligomer research. Using the small amine-reactive cross-linker, formaldehyde (FA), we successfully stabilized
17 α-syn oligomers without affecting their size, overall structure or antigenicity towards aggregate-
18 conformation specific α-syn antibodies FILA and MJFR-14-6-4-2. Further, cross-linked α-syn oligomers show
19 resistance towards denaturant like urea and SDS treatment and remain fully functional as internal standard
20 in an aggregation-specific enzyme-linked immunosorbent assay (ELISA) despite prior incubation with urea.
21 We propose that FA cross-linked α-syn oligomers could serve as important calibrators to facilitate
22 comparative and standardized α-syn biomarker studies going forward.

23

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

24 **Introduction**

25 Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) are the three
26 main types of synucleinopathies, all of which are characterized by inclusions mainly consisting of intracellular
27 aggregated α-synuclein (α-syn); a 140-amino acid protein with hypothesized unfolded native appearance [1,
28 2]. α-syn is widely expressed in the brain and mainly localizes to the presynaptic terminals where it is believed
29 to play a role as a SNARE-complex chaperone, necessary for binding of vesicles and the release of
30 neurotransmitter in the synaptic cleft [3, 4]. Proof of the involvement of α-syn in PD is evident from familial
31 cases, where specific point mutations or multiple copies of the normal α-syn gene, SNCA, causes autosomal
32 PD [5-8]. Under normal physiological conditions, α-syn exists as a native species in the brain, but aggregates
33 into larger insoluble fibrils under pathological conditions [9]. However, α-syn also exists in an intermediate
34 state, as an aggregated soluble species, called oligomers. Oligomers have been found in post-mortem brain
35 extracts from both DLB, PD and MSA patients [10-12], and accumulating evidence indicates that oligomers
36 are responsible for the toxicity seen in the brain of patients suffering from synucleinopathies [13-15].
37 Furthermore, *in vitro* generated oligomers are capable of seeding and mediate cell-to-cell spreading linked
38 to the prion-like spreading seen in PD [16]. α-syn oligomers can be generated in vitro in several ways, such
39 as chemical modification by dopamine, ethanol and Fe^{3+} and high protein concentration [17-19]. Oligomers
40 formed spontaneously at high protein concentration have also shown similarities with patient-derived *in vivo*
41 oligomers in the antigenicity towards aggregation-specific antibodies [10]. However, these oligomers are
42 metastable and dissociate into monomers over time [20]. Therefore, an *in vivo* representative α-syn
43 oligomer-standard used to study the underlying mechanistic pathways and aid in the search for
44 synucleinopathy-specific biomarkers, is of great interest. Using formaldehyde (FA) crosslinking, we have
45 successfully stabilized α-syn in its oligomeric state without disturbing antigenicity and biochemical
46 properties, thereby providing a much-needed calibrating tool, which enables comparative and standardized
47 research within the field of oligomeric α-syn.

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

48 **Results**

49 **Characterizing native α-syn oligomers**

50 Brief incubating of high concentration of α-syn at 0°C has previously been shown to spontaneously generate
51 oligomeric species [19-21]. Using this method, in combination with size-exclusion chromatography, we
52 successfully separated oligomers from monomers and obtained a pure oligomeric fraction (Fig 1A). Dynamic
53 light scattering (DLS) confirmed the different sizes of the α-syn monomers and oligomers, showing two
54 distinct species, with an average radius of 3.6 ± 0.3 and 49.7 ± 2.6 nm respectively (Fig. 1B). Monomers and
55 oligomers both bind the α-syn specific antibodies BD and ASY1 that recognizes total α-syn levels, whereas
56 only the oligomers specifically binds the two aggregation-specific antibodies, FILA and MJF14 (Fig. 1C).
57 Transmission electron microscopy (TEM) revealed a twisted ribbon-like structure of the purified α-syn
58 oligomers, which corresponds well with previous observation of oligomeric α-syn (Fig. 1D) [22]. The α-syn
59 oligomers clearly differ from the well-ordered structure and size of the preformed α-syn fibrils (Fig. 1E).

60

61 **Stabilization of the α-syn oligomers using formaldehyde**

62 α-syn oligomers consist of non-covalently bound monomers that easily dissociate into monomers upon
63 boiling in SDS prior to SDS-PAGE (Fig. 2A, right). However, incubation of the α-syn oligomers with increasing
64 concentration of the small amine-reactive cross-linker, formaldehyde (FA), prior to SDS-PAGE, stabilized the
65 α-syn multimers as evident from a depletion of the ~17kDa monomeric α-syn band (Fig. 2A, right). The
66 retention of immunoreactivity in the stacking gel demonstrates the cross-linking of α-syn into large stable
67 complexes (Fig 2A, right). By contrast α-syn monomers incubated with identical FA concentrations did not
68 result in cross-linked-dependent depletion of the monomeric band nor accumulation of high molecular
69 weight species (Fig 2A, left).

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

70 Visualization of FA-treated monomeric and oligomeric α-syn, using the aggregation-specific FILA antibody,
71 revealed that epitope-recognition was unaffected by cross-linking (Fig. 2B). The FA treated oligomers are also
72 less prone to disassembly, as FILA antigenicity after 3h incubation with denaturizing SDS, is still observed (Fig.
73 2B).

74

75 **Optimization of cross-linking**

76 To avoid excessive and unnecessary chemical modification of the oligomers, we carried out titration
77 experiments, aiming to find the lowest possible concentration of FA that efficiently stabilize α-syn oligomers.
78 Using 0.2-3.2% FA and incubation for 30- or 60 min, we found that 1.6% and 3.2% FA after 60 min resulted in
79 satisfactory cross-linking as measured by loss of the α-syn monomer-band (95 ± 4.6% and 98 ± 1.9%
80 respectively), when resolved on SDS-PAGE (Fig. 3A-C). Further, we assessed if antigenicity of α-syn monomers
81 or oligomers were affected by FA cross-linking. No difference was observed in oligomer recognition using
82 antibodies BD, ASY1, FILA and MJF14 at any concentration of FA (Fig. 3D-G), although a trend of high FA
83 concentrations masking the BD epitope of monomeric α-syn was observed (Fig. 3E). 3.2% FA incubation
84 generally results in a slightly higher cross-linking efficiency than 1.6% FA (Fig. 3A and 3C), but we chose to
85 continue with 1.6% FA for the remainder of the study for technical reasons. Primarily to avoid unnecessary
86 dilution of the oligomers by adding larger volumes of Tris to quench the FA cross-linker.

87

88 **PFA stabilized α-syn retain biophysical and experimental properties**

89 To test the biophysical properties of the 1.6% FA cross-linked oligomers, we performed a DLS time-course
90 experiment, measuring the size-distribution of the oligomers after 0, 15, 30 and 60 min of 1.6% FA treatment.
91 Throughout the experiment, the size of the oligomers was unchanged, suggesting that the oligomers are
92 stabilized in their native structure and not cross-linked into larger complexes over time (Fig. 4A). EM

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

93 confirmed that the overall structure of the oligomers were kept after FA mediated cross-linking as these
94 resembled native oligomers (Fig. 1D and 4B).

95 *In vitro* formed α-syn oligomers are useful in many experimental setups. One example, is the application of
96 *in vitro* α-syn oligomers as internal standard in the newly developed aggregation-specific enzyme-linked
97 immunosorbent assay (ELISA) based on the aggregation-specific MJF14 antibody [23]; an assay that
98 effectively assess levels of α-syn oligomers in cell and animal models. Using this method, we compared the
99 standard curves prepared from either native oligomers or FA cross-linked oligomers under different
100 conditions (Fig. 4C). We observed that ELISA standard curves using cross-linked oligomers were
101 indistinguishable from those prepared with native oligomers (Fig. 4C). Moreover, while pretreatment of
102 native oligomers with 6M urea clearly abolish the MJF14 ELISA signal, FA cross-linked oligomers remained
103 stable and created reliable standard curves despite exposure to high concentration urea (Fig. 4C). Together,
104 these findings demonstrate that FA treatment effectively cross-link and stabilize native oligomers without
105 disturbing size, structure and antibody recognition of the oligomers.

106

107

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

108 **Discussion**

109 Mounting evidence suggest a central role of soluble α-syn oligomers as toxic species relevant to the
110 progressive spreading of α-syn pathology in the nervous system in synucleinopathies [24] and quantification
111 of such species holds great potential as biomarkers [25-27].

112 In vitro formed α-syn oligomers represents a very heterogenous group that either presents as annular-,
113 spherical-, circular-, rod shaped-, amorphous- and twisted ribbon-like structures dependent on the method
114 of preparation and visualization [19, 21, 28]. Their diverse size, biochemical and structural properties likely
115 make them dissimilar with respect to their presentation of antigens towards conformation specific-
116 antibodies as demonstrated for insoluble α-syn strains [28, 29]. Moreover their semistable nature makes
117 them unsuitable as analytical calibration standards in bioassays [20].

118 We successfully cross-linked α-syn oligomers using FA, thereby increasing stability towards SDS and urea
119 denaturation. This oligomer preparation binds neuronal proteins in a conformational specific manner [21,
120 22], and also bind the two conformational specific antibodies FILA and MJF14. The FA mediated crosslinking
121 did not disturb the overall twisted ribbon-like oligomeric structure, the size of the oligomers, their
122 antigenicity toward FILA and MJF14 or the crosslinked oligomers applicability as calibrators in an α-syn
123 oligomer specific ELISA assay [23]. Hence we propose this FA cross-linked α-syn oligomer preparation could
124 serve as calibrators that facilitates comparative and standardized biomarker studies in the synucleinopathies.

125

126

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

127 ## Materials and methods

128 ### Antibodies

129 Primary antibodies: α-syn monoclonal mouse-anti-α-syn (BD Biosciences, catalog no. 610787), polyclonal
130 rabbit-anti-α-syn (ASY1 [30]), α-syn aggregate-specific antibodies FILA5 (polyclonal rabbit-antibody, in house
131 generated [31]), and MJFR-14-6-4-2 (MJF14) (abcam, catalog no. 209538, rabbit monoclonal antibody,
132 generated against full length α-syn protein filament). Secondary antibodies: horseradish peroxidase (HRP)-
133 conjugated polyclonal rabbit-anti-mouse (Dako, P0260), HRP-conjugated polyclonal swine-anti-rabbit (Dako,
134 P0217).

135 ### Oligomer preparation

136 Production of α-syn and α-syn oligomers was performed as previously described [19, 21, 32]. In short, purified
137 α-syn was dissolved in PBS to a final concentration of 10mg/mL and incubated on ice for 30 minutes while
138 vortexed regularly. After incubation, α-syn was centrifuged at 12000g for 5 minutes and the supernatant
139 loaded onto a Superdex™ 200 10/300 GL column (GE Healthcare). The column was eluted with PBS at a flow
140 rate of 0.5 mL/minute. Oligomers were collected between 18- 22 min and monomers after 38-43 min. All
141 collected fractions were snap frozen on dry ice and stored at -80°C.

142 ### Crosslinking

143 Monomers and oligomers were crosslinked at a final protein concentration of 10-15ng/µL. Formaldehyde 37-
144 38% w/w (PanReac AppliChem) was diluted in H_2O and filtered (0,45µm) before use. FA crosslinker was added
145 in a 2x concentration to samples to obtain final concentration. Crosslinking was performed at 37°C and
146 quenched with Tris (two times molar concentration of FA) for a minimum of 15 minutes at RT prior to dialysis
147 in PBS.

148 ### Immunoblotting

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

149 For Western blotting, samples were boiled for 5 min at 95°C for in loading buffer (50 mM Tris pH 6.8, 40%
150 glycerol, 4% SDS, bromophenol blue) without reducing agent before loading onto a 4-16% PAGE gel
151 (GenScript ExpressPlus™). Gels were blotted on PVDF membranes and fixed in 4% formaldehyde for 30
152 minutes and boiled in PBS for 5 minutes. For dot blotting 50-100ng of protein was blotted on nitrocellulose
153 (Hydrobond-C Extra, GE Healthcare) and these filters were not fixed or boiled. All membranes were blocked
154 in non-fat milk (TBS with 5% non-fat milk, 0.05% Tween 20 and 0.02% sodium azide) for 30 minutes at RT
155 followed by incubation with primary antibodies overnight. membranes were washed in TBS-T (TBS with 0.1%
156 Tween) and incubated with secondary antibodies for 1.5 hour. Membranes were washed, developed using
157 ECL reagent (Pierce™, Thermo Scientific), and subsequently imaged on a LAS-3000 imaging system (Fuji). Blot
158 quantification was done using ImageJ

159 **Size determination using Dynamic Light Scatter**

160 For size determination using Dynamic Light Scattering (DLS) samples were placed in a disposable cuvette and
161 analyzed using a Wyatt Technology DynaPro NanoStar. Laser strength was set to 100% and scatter angle fixed
162 at 90°. Total samples measurement where assembled via 10 consecutive 5 second measurements. Prior to
163 analysis, samples were centrifuged for 3 minutes at >12000g. Data was analyzed with Dynamics V7.5.0.17.

164 **Negative staining transmission electron microscopy**

165 Negative staining transmission electron microscopy (TEM) was performed as described previously [33, 34].
166 In brief, 3µL of sample was loaded onto a glow discharged carbon coated copper grid and stained with 2%
167 uranyl formate. Images were collected using a Tecnai G2 Spirit TWIN electron microscope in combination
168 with a Tietz TemCam-F416 CMOS camera at a magnification of 54000x to 67000x. Samples for EM were
169 crosslinked in PBS and dialyzed, with three buffer changes, to TBS to avoid precipitation of phosphate with
170 uranyl. Sample to dialyzing buffer volume ratio 1:100.

171 **Enzyme-linked immunosorbent assay**

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

172 ELISA analysis was carried out as previously described [23]. In summary, 62.5 ng/mL MJF14 antibody and 0.5
173 µg/mL BD antibody were used as capture and detection antibody, respectively. 1,1 µg/mL native and
174 crosslinked α-syn oligomer were incubated without or in the presence of 6 M urea for 6 hours at RT, before
175 being analyzed by ELISA in at dilution ranging from 20 ng/mL to 313 pg/mL.

176 **Statistical analysis**

177 Data was statistically analyzed and visualized using GraphPad Prism 7. Data was tested with a one-way
178 ANOVA followed by Bonferroni post hoc analysis. For ELISA experiment, two-way ANOVA for repeated
179 measures followed by Tukey's multiple comparison test was used. Differences were considered significant
180 for *$p<0.05$, **$p<0.01$, ***$p<0.001$, ****$p<0.0001$. Data is presented as means ± SD.

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

181 **References**

182 1. Goedert, M., *Alpha-synuclein and neurodegenerative diseases.* Nat Rev Neurosci, 2001. **2**(7): p. 492-
183 501.
184 2. Eliezer, D., E. Kutluay, R. Bussell, Jr., and G. Browne, *Conformational properties of alpha-synuclein in*
185 *its free and lipid-associated states.* J Mol Biol, 2001. **307**(4): p. 1061-73.
186 3. Iwai, A., E. Masliah, M. Yoshimoto, N. Ge, L. Flanagan, H.A. de Silva, et al., *The precursor protein of*
187 *non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous*
188 *system.* Neuron, 1995. **14**(2): p. 467-75.
189 4. Burre, J., M. Sharma, T. Tsetsenis, V. Buchman, M.R. Etherton, and T.C. Sudhof, *Alpha-synuclein*
190 *promotes SNARE-complex assembly in vivo and in vitro.* Science, 2010. **329**(5999): p. 1663-7.
191 5. Chartier-Harlin, M.C., J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S. Lincoln, et al., *Alpha-*
192 *synuclein locus duplication as a cause of familial Parkinson's disease.* Lancet, 2004. **364**(9440): p.
193 1167-9.
194 6. Kruger, R., W. Kuhn, T. Muller, D. Woitalla, M. Graeber, S. Kosel, et al., *Ala30Pro mutation in the gene*
195 *encoding alpha-synuclein in Parkinson's disease.* Nat Genet, 1998. **18**(2): p. 106-8.
196 7. Polymeropoulos, M.H., C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, et al., *Mutation in the*
197 *alpha-synuclein gene identified in families with Parkinson's disease.* Science, 1997. **276**(5321): p.
198 2045-7.
199 8. Zarranz, J.J., J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, I. Ampuero, et al., *The new mutation,*
200 *E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.* Ann Neurol, 2004. **55**(2): p. 164-
201 73.
202 9. Spillantini, M.G., M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert, *Alpha-synuclein*
203 *in Lewy bodies.* Nature, 1997. **388**(6645): p. 839-40.

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

204 10. Paleologou, K.E., C.L. Kragh, D.M. Mann, S.A. Salem, R. Al-Shami, D. Allsop, et al., *Detection of*
205 *elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with*
206 *dementia with Lewy bodies.* Brain, 2009. **132**(Pt 4): p. 1093-101.
207 11. Roberts, R.F., R. Wade-Martins, and J. Alegre-Abarrategui, *Direct visualization of alpha-synuclein*
208 *oligomers reveals previously undetected pathology in Parkinson's disease brain.* Brain, 2015. **138**(6):
209 p. 1642-1657.
210 12. Sekiya, H., H. Kowa, H. Koga, M. Takata, W. Satake, N. Futamura, et al., *Wide distribution of alpha-*
211 *synuclein oligomers in multiple system atrophy brain detected by proximity ligation.* Acta
212 Neuropathol, 2019. **137**(3): p. 455-466.
213 13. Winner, B., R. Jappelli, S.K. Maji, P.A. Desplats, L. Boyer, S. Aigner, et al., *In vivo demonstration that*
214 *alpha-synuclein oligomers are toxic.* Proc Natl Acad Sci U S A, 2011. **108**(10): p. 4194-9.
215 14. Karpinar, D.P., M.B.G. Balija, S. Kügler, F. Opazo, N. Rezaei-Ghaleh, N. Wender, et al., *Pre-fibrillar α-*
216 *synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models.* The
217 EMBO Journal, 2009. **28**(20): p. 3256-3268.
218 15. Ludtmann, M.H.R., P.R. Angelova, M.H. Horrocks, M.L. Choi, M. Rodrigues, A.Y. Baev, et al., *alpha-*
219 *synuclein oligomers interact with ATP synthase and open the permeability transition pore in*
220 *Parkinson's disease.* Nat Commun, 2018. **9**(1): p. 2293.
221 16. Danzer, K.M., S.K. Krebs, M. Wolff, G. Birk, and B. Hengerer, *Seeding induced by alpha-synuclein*
222 *oligomers provides evidence for spreading of alpha-synuclein pathology.* J Neurochem, 2009. **111**(1):
223 p. 192-203.
224 17. Danzer, K.M., D. Haasen, A.R. Karow, S. Moussaud, M. Habeck, A. Giese, et al., *Different species of*
225 *alpha-synuclein oligomers induce calcium influx and seeding.* J Neurosci, 2007. **27**(34): p. 9220-32.
226 18. Cappai, R., S.L. Leck, D.J. Tew, N.A. Williamson, D.P. Smith, D. Galatis, et al., *Dopamine promotes*
227 *alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway.*
228 Faseb j, 2005. **19**(10): p. 1377-9.

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

229 19. Lashuel, H.A., B.M. Petre, J. Wall, M. Simon, R.J. Nowak, T. Walz, et al., *Alpha-synuclein, especially*
230 *the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.* J Mol
231 Biol, 2002. **322**(5): p. 1089-102.
232 20. Mysling, S., C. Betzer, P.H. Jensen, and T.J.D. Jorgensen, *Characterizing the Dynamics of α-Synuclein*
233 *Oligomers Using Hydrogen/Deuterium Exchange Monitored by Mass Spectrometry.* Biochemistry,
234 2013. **52**(51): p. 9097-9103.
235 21. Betzer, C., A.J. Movius, M. Shi, W.P. Gai, J. Zhang, and P.H. Jensen, *Identification of synaptosomal*
236 *proteins binding to monomeric and oligomeric alpha-synuclein.* PLoS One, 2015. **10**(2): p. e0116473.
237 22. Betzer, C., L.B. Lassen, A. Olsen, R.H. Kofoed, L. Reimer, E. Gregersen, et al., *Alpha-synuclein*
238 *aggregates activate calcium pump SERCA leading to calcium dysregulation.* EMBO Rep, 2018. **19**(5).
239 23. Lassen, L.B., E. Gregersen, A.K. Isager, C. Betzer, R.H. Kofoed, and P.H. Jensen, *ELISA method to detect*
240 *α-synuclein oligomers in cell and animal models.* PLoS ONE, 2018. **13**(4): p. e0196056.
241 24. Ono, K., *The Oligomer Hypothesis in α-Synucleinopathy.* Neurochemical Research, 2017. **42**(12): p.
242 3362-3371.
243 25. El-Agnaf, O.M., S.A. Salem, K.E. Paleologou, M.D. Curran, M.J. Gibson, J.A. Court, et al., *Detection of*
244 *oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's*
245 *disease.* Faseb j, 2006. **20**(3): p. 419-25.
246 26. Park, M.J., S.-M. Cheon, H.-R. Bae, S.-H. Kim, and J.W. Kim, *Elevated levels of α-synuclein oligomer in*
247 *the cerebrospinal fluid of drug-naïve patients with Parkinson's disease.* Journal of clinical neurology
248 (Seoul, Korea), 2011. **7**(4): p. 215-222.
249 27. Tokuda, T., M.M. Qureshi, M.T. Ardah, S. Varghese, S.A. Shehab, T. Kasai, et al., *Detection of elevated*
250 *levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease.* Neurology, 2010.
251 **75**(20): p. 1766-72.

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

252 28. Cremades, N., S.W. Chen, and C.M. Dobson, *Chapter Three - Structural Characteristics of α-Synuclein*
253 *Oligomers*, in *International Review of Cell and Molecular Biology*, M. Sandal, Editor. 2017, Academic
254 Press. p. 79-143.
255 29. Bousset, L., L. Pieri, G. Ruiz-Arlandis, J. Gath, P.H. Jensen, B. Habenstein, et al., *Structural and*
256 *functional characterization of two alpha-synuclein strains.* Nat Commun, 2013. **4**: p. 2575.
257 30. Jensen, P.H., K. Islam, J. Kenney, M.S. Nielsen, J. Power, and W.P. Gai, *Microtubule-associated protein*
258 *1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments.* J Biol Chem, 2000.
259 **275**(28): p. 21500-7.
260 31. Lindersson, E., R. Beedholm, P. Hojrup, T. Moos, W. Gai, K.B. Hendil, et al., *Proteasomal inhibition by*
261 *alpha-synuclein filaments and oligomers.* J Biol Chem, 2004. **279**(13): p. 12924-34.
262 32. Huang, C., G. Ren, H. Zhou, and C.C. Wang, *A new method for purification of recombinant human*
263 *alpha-synuclein in Escherichia coli.* Protein Expr Purif, 2005. **42**(1): p. 173-7.
264 33. Gewering, T., D. Januliene, A.B. Ries, and A. Moeller, *Know your detergents: A case study on detergent*
265 *background in negative stain electron microscopy.* J Struct Biol, 2018. **203**(3): p. 242-246.
266 34. Tao, H., S.C. Lee, A. Moeller, R.S. Roy, F.Y. Siu, J. Zimmermann, et al., *Engineered nanostructured β-*
267 *sheet peptides protect membrane proteins.* Nature methods, 2013. **10**(8): p. 759-761.

268

269

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

270 **Figure legends**

271 ***Figure 1. Generation and confirmation of in vitro generated α-syn oligomers and fibrils A)*** *Oligomers*
272 *generated by resuspending lyophilised recombinant α-syn at high concentration (10mg/mL) incubated on ice*
273 *and subsequently isolated using gel-filtration. Oligomers (O) are collected between 18- 22 min. and monomers*
274 *(M) between 38-43 min.* ***B)*** *Hydrodynamic radius in nm of isolated particles was determined using DLS. Graph*
275 *shows a merged image of the hydrodynamic radius (x-axis) of oligomers (dark grey) and monomers (white).*
276 *Intensity of signal is depicted on the y-axis* ***C)*** *Antigenicity of oligomers and monomers to BD, FILA5, MJF14*
277 *and ASY1 was determined using dot blot. Dots consist of 50ng protein spotted in duplicates. Negative stain*
278 *EM image shows ultrastructure of native α-syn oligomer* ***D)*** *and* ***E)*** *ultrastructure of in vitro* formed *α-syn*
279 *fibrils.*

280

281 ***Figure 2. Crosslinking of α-syn monomers and oligomers****.* ***A)*** *α-syn monomers and oligomers were crosslinked*
282 *with FA at different concentrations. Immunoblot of monomers (left) and oligomers (right) show ASY1 binding.*
283 *Monomeric α-syn situates at ~17kDa. Depletion of the ~17kDa α-syn band and presence of ASY-1 reactivity in*
284 *the stacking gel suggest efficient cross-linking upon FA treatment of oligomers.* ***B)*** *Dot blot of 100ng non-*
285 *treated- or 1.6% FA cross-linked α-syn monomers and oligomers using aggregation-specific FILA5 antibody.*
286 *Prior to dot-blot, one subset of native- and cross-linked oligomers were treated with 0.4% SDS for 1 h. to*
287 *assess oligomer stability.*

288

289 **Figure 3. Optimization of α-syn oligomer cross-linking A-C)** α-syn oligomers were crosslinked with FA in a
290 concentration of 0-3.2% for 30- or 60 min and subjected to immunoblot using ASY1 antibody to detect α-syn
291 species (A). Monomer ~17kDa ASY-1 positive bands were quantified to assess degree of cross-linking and
292 results are shown in B and C. Bar graphs show means ± SD obtained in three individual experiments. **D-G)**

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

293 Monomers (black bars) and oligomers (grey bars) were cross-linked using different FA concentrations (0%-
294 3.2% FA) for 60 min. The antigenicity of cross-linked monomers and oligomers were assessed via dot blot
295 using ASY1 (D), BD (E), FILA5 (F) and MJF14 (G) antibodies. Figures show means ± SD of three independent
296 experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n.s.= not significant.

297

298 ***Figure 4. Oligomers cross-linked using FA maintain their size and structure and resist denaturation A)***
299 *Hydrodynamic radius of oligomers was monitored during 1.6% FA cross-linking using DLS. Measurements*
300 *were taken before FA treatment (0 min) and 15-, 30- and 60 min after initiation of cross-linking.* ***B)*** *Negative*
301 *stain EM image shows ultrastructure of α-syn oligomer cross-linked for 60 min using 1.6% FA.* ***C)*** *Native and*
302 *1.6% FA crosslinked α-syn oligomer were treated with 6M Urea for 6h at RT or left untreated. Serial dilutions*
303 *were analyzed by ELISA as previously described by Lassen et al. [23], utilizing the aggregated specific antibody*
304 *MJF14. The levels are measured as absorbance at 450 nm. Two-way ANOVA for repeated measures followed*
305 *by Tukey's multiple comparison test was used for ELISA experiment.*

306

307

308 **Acknowledgement**

309 The study was supported by Michael J Fox grant 13750 and Lundbeck foundation grants R223-2015-4222,
310 R248-2016-25, R248-2016-2518 Danish Research Institute of Translational Neuroscience - DANDRITE, Nordic-
311 EMBL Partnership for Molecular Medicine

312











Figure 1





Figure 2

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



Figure 3

bioRxiv preprint doi: https://doi.org/10.1101/623538; this version posted April 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.







Figure 4